Stakeholder Insight: HIV Related Neuropathic Pain - Useful Niche for Peripheral Companies

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2004-05-03

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Fueled by the growing interest in neuropathic pain but keen to avoid competition with larger players, small companies recognize the commercial opportunity of the HIV-related neuropathic pain (HIVNP) market. Not only does HIVNP offer a well-served patient base and good awareness, it is also a useful stepping-stone to larger more prevalent neuropathic pain types and thus greater commercial gains.


Scope

  • Quantitative treatment data from over 171 physicians from the US, France, Germany, Italy, and the UK
  • Analysis of epidemiology, assessment and referral patterns, first- to third-line treatments, and unmet market needs
  • Discussion of the R&D drug pipeline for HIVNP, with analysis of NeurogesX�s patch analgesic NGX-4010 and Savient�s nerve growth stimulator Prosaptide
  • Coverage of the hot topics including education of HIV specialists, reducing pill burden, and the potential of pathogenesis-based treatments


    • Report Highlights
    In countries such as the US and the UK there is a strong therapeutic relationship between HIVNP patients and HIV specialists. Although patients tend to be well served and treatment initiated reasonably early, there is still a need to educate HIV physicians on HIVNP management.

    The tricyclic antidepressant amitriptyline is a popular treatment of neuropathic pain across the 7 markets, although its side effects are intolerable to many HIVNP patients. The newer serotonin and noradrenaline reuptake inhibitor class of antidepressants, however, appears to offer a cleaner side effect profile with equivalent analgesic ability.

    In the long-term, the future HIVNP market will see the launch of pathogenesis-based therapies, such as nerve growth factor agonists. However, while the search for effective neurotrophic compounds that can halt or ideally reverse nerve damage causing HIVNP continues, analgesics will remain an important part of pain management.


    Reasons to Purchase

  • Forecast product sales by understanding key aspects of HIVNP epidemiology, referral, diagnosis, treatment, and unmet needs
  • Improve pain product positioning strategies by realizing the commercial advantages offered by the HIVNP niche
  • Understand how the HIVNP market provides an opening to more profitable neuropathic pain indications in the US

    • Table of Contents

    Other users found this report page using the following search terms: hiv neuropathic pain pain hiv pain neuropathic related neuropathy niche top pharmaceuticle enlander 3

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.